Equities Analysts Offer Predictions for Hologic, Inc.’s Q2 2018 Earnings (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Jefferies Group decreased their Q2 2018 earnings per share estimates for Hologic in a report released on Wednesday. Jefferies Group analyst R. Denhoy now expects that the medical equipment provider will post earnings of $0.56 per share for the quarter, down from their prior estimate of $0.57. Jefferies Group has a “Buy” rating and a $49.00 price objective on the stock. Jefferies Group also issued estimates for Hologic’s Q3 2018 earnings at $0.59 EPS, Q4 2018 earnings at $0.59 EPS, FY2018 earnings at $2.28 EPS, FY2019 earnings at $2.59 EPS and FY2020 earnings at $2.96 EPS.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The business had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same period in the previous year, the business earned $0.51 earnings per share. The business’s revenue was up 12.4% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: “Equities Analysts Offer Predictions for Hologic, Inc.’s Q2 2018 Earnings (NASDAQ:HOLX)” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://theolympiareport.com/2017/08/08/equities-analysts-offer-predictions-for-hologic-inc-s-q2-2018-earnings-nasdaqholx.html.

A number of other equities research analysts have also recently commented on the company. Goldman Sachs Group, Inc. (The) cut Hologic from a “conviction-buy” rating to a “buy” rating and dropped their target price for the company from $48.00 to $47.00 in a research report on Thursday, August 3rd. Stifel Nicolaus restated a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Canaccord Genuity restated a “buy” rating and set a $53.00 target price on shares of Hologic in a research report on Tuesday, May 9th. Zacks Investment Research cut Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, BTIG Research restated a “buy” rating and set a $47.00 target price on shares of Hologic in a research report on Sunday, May 14th. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $48.64.

Hologic (NASDAQ HOLX) traded down 0.56% during midday trading on Monday, hitting $38.81. The company had a trading volume of 1,147,624 shares. Hologic has a 1-year low of $35.15 and a 1-year high of $46.80. The company has a 50 day moving average price of $45.06 and a 200 day moving average price of $42.98. The firm has a market capitalization of $10.89 billion, a P/E ratio of 14.45 and a beta of 0.90.

In other Hologic news, VP Karleen Marie Oberton sold 4,704 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $45.19, for a total value of $212,573.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 9,837 shares of the firm’s stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $45.34, for a total transaction of $446,009.58. Following the completion of the transaction, the director now directly owns 40,577 shares in the company, valued at $1,839,761.18. The disclosure for this sale can be found here. Insiders sold a total of 70,464 shares of company stock worth $3,078,921 over the last three months. Corporate insiders own 0.79% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors raised its position in Hologic by 11.2% in the first quarter. Nationwide Fund Advisors now owns 511,970 shares of the medical equipment provider’s stock worth $21,784,000 after buying an additional 51,676 shares during the period. State of Alaska Department of Revenue acquired a new position in Hologic during the first quarter worth $530,000. Nisa Investment Advisors LLC raised its position in Hologic by 60.9% in the first quarter. Nisa Investment Advisors LLC now owns 86,602 shares of the medical equipment provider’s stock worth $3,685,000 after buying an additional 32,782 shares during the period. DnB Asset Management AS raised its position in Hologic by 13.4% in the first quarter. DnB Asset Management AS now owns 19,505 shares of the medical equipment provider’s stock worth $830,000 after buying an additional 2,300 shares during the period. Finally, Gateway Investment Advisers LLC raised its position in Hologic by 12.5% in the first quarter. Gateway Investment Advisers LLC now owns 489,358 shares of the medical equipment provider’s stock worth $20,822,000 after buying an additional 54,208 shares during the period. 94.46% of the stock is currently owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hologic Inc. and related companies with Analyst Ratings Network’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

10 − five =